 |
9 Diseases |  |
2 Trials |
|
2 Trials |  |
71 News |  |
| 12» |
- ||| GI-6301 / BMS
Trial completion, Enrollment change, Combination therapy, Metastases: QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma (clinicaltrials.gov) - May 20, 2024
P2, N=24, Completed, Sponsor: NantCell, Inc.
Unknown status --> Completed | N=55 --> 24
- || Trial completion date, Trial primary completion date: QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. (clinicaltrials.gov) - Sep 28, 2023
P1/2, N=79, Active, not recruiting, Sponsor: ImmunityBio, Inc.
Unknown status --> Completed | N=55 --> 24 Trial completion date: Jan 2023 --> Oct 2023 | Trial primary completion date: Dec 2022 --> Sep 2023
- || Trial completion date, Trial primary completion date: QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. (clinicaltrials.gov) - Mar 29, 2022
P1/2, N=79, Active, not recruiting, Sponsor: ImmunityBio, Inc.
Trial completion date: Jan 2023 --> Oct 2023 | Trial primary completion date: Dec 2022 --> Sep 2023 Trial completion date: Jan 2020 --> Jan 2023 | Trial primary completion date: Dec 2019 --> Dec 2022
- || Trial completion date, Trial primary completion date, Metastases: QUILT-3.071: QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine (clinicaltrials.gov) - Mar 29, 2022
P1b/2, N=332, Active, not recruiting, Sponsor: ImmunityBio, Inc.
Trial completion date: Jan 2020 --> Jan 2023 | Trial primary completion date: Dec 2019 --> Dec 2022 Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
- || GI-6301 / BMS
Clinical, P2 data, Journal, Combination therapy: Randomized, Double-Blind, Placebo-Controlled Phase II Study of Yeast-Brachyury Vaccine (GI-6301) in Combination with Standard-of-Care Radiotherapy in Locally Advanced, Unresectable Chordoma. (Pubmed Central) - Jul 7, 2021
While the combination of yeast-brachyury vaccine (GI-6301) and standard radiation therapy did not demonstrate synergistic antitumor effects, brachyury still remains a good target for developmental therapeutics in chordoma. Patients and their oncologists should consider early referral to centers with expertise in chordoma (or sarcoma) and encourage participation in clinical trials.
- || Trial primary completion date, Metastases: QUILT-3.071: QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine (clinicaltrials.gov) - Sep 17, 2020
P1b/2, N=332, Active, not recruiting, Sponsor: NantKwest, Inc.
Patients and their oncologists should consider early referral to centers with expertise in chordoma (or sarcoma) and encourage participation in clinical trials. Trial primary completion date: Dec 2019 --> Dec 2021
- || Trial completion date, Trial primary completion date: QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed (clinicaltrials.gov) - Aug 11, 2020
P1/2, N=65, Active, not recruiting, Sponsor: NantKwest, Inc.
Trial primary completion date: Dec 2019 --> Dec 2021 Trial completion date: Dec 2019 --> Apr 2021 | Trial primary completion date: Dec 2019 --> Jan 2021
- GI-6301 / BMS
[VIRTUAL] A randomized, double-blind, phase II clinical trial of GI-6301 (yeast-brachyury vaccine) versus placebo in combination with standard of care definitive radiotherapy in locally advanced, unresectable, chordoma. (Poster Board 415) - Apr 29, 2020 - Abstract #ASCO2020ASCO_2550;
P2
GI-6301 was well tolerated with toxicities related to RT, not vaccine. The trial was stopped early due to low conditional power for finding a statistical difference at the planned end of accrual, based on findings to date.
- || GI-6301 / BMS
Trial primary completion date, Combination therapy, Metastases: QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma (clinicaltrials.gov) - Oct 28, 2019
P2, N=55, Active, not recruiting, Sponsor: NantCell, Inc.
The trial was stopped early due to low conditional power for finding a statistical difference at the planned end of accrual, based on findings to date. Trial primary completion date: Mar 2019 --> Mar 2020
- | Enrollment change, Trial withdrawal: QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy (clinicaltrials.gov) - Aug 29, 2019
P1/2, N=0, Withdrawn, Sponsor: NantKwest, Inc.
Trial primary completion date: Mar 2019 --> Mar 2020 N=79 --> 0 | Not yet recruiting --> Withdrawn
- | Enrollment change, Trial withdrawal: QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy (clinicaltrials.gov) - Aug 28, 2019
P1/2, N=0, Withdrawn, Sponsor: NantKwest, Inc.
N=79 --> 0 | Not yet recruiting --> Withdrawn N=113 --> 0 | Not yet recruiting --> Withdrawn
- | Enrollment change, Trial withdrawal: QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy (clinicaltrials.gov) - Aug 28, 2019
P1/2, N=0, Withdrawn, Sponsor: NantKwest, Inc.
N=113 --> 0 | Not yet recruiting --> Withdrawn N=67 --> 0 | Not yet recruiting --> Withdrawn
- | Enrollment change, Trial withdrawal: QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors (clinicaltrials.gov) - Aug 28, 2019
P1/2, N=0, Withdrawn, Sponsor: NantKwest, Inc.
N=67 --> 0 | Not yet recruiting --> Withdrawn N=85 --> 0 | Not yet recruiting --> Withdrawn
- | Enrollment change, Trial withdrawal: QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy (clinicaltrials.gov) - Aug 28, 2019
P1/2, N=0, Withdrawn, Sponsor: NantKwest, Inc.
N=85 --> 0 | Not yet recruiting --> Withdrawn N=113 --> 0 | Not yet recruiting --> Withdrawn
- | Enrollment change, Trial withdrawal, Metastases: QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC (clinicaltrials.gov) - Aug 28, 2019
P1/2, N=0, Withdrawn, Sponsor: NantKwest, Inc.
N=113 --> 0 | Not yet recruiting --> Withdrawn N=79 --> 0 | Not yet recruiting --> Withdrawn
- | Enrollment change, Trial withdrawal: QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy (clinicaltrials.gov) - Aug 28, 2019
P1/2, N=0, Withdrawn, Sponsor: NantKwest, Inc.
N=79 --> 0 | Not yet recruiting --> Withdrawn N=67 --> 0 | Not yet recruiting --> Withdrawn
- | Enrollment change, Trial withdrawal: QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy (clinicaltrials.gov) - Aug 28, 2019
P1/2, N=0, Withdrawn, Sponsor: NantKwest, Inc.
N=67 --> 0 | Not yet recruiting --> Withdrawn N=67 --> 0 | Not yet recruiting --> Withdrawn
- | Enrollment change, Trial withdrawal: QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer (clinicaltrials.gov) - Aug 28, 2019
P2, N=0, Withdrawn, Sponsor: NantKwest, Inc.
N=67 --> 0 | Not yet recruiting --> Withdrawn N=558 --> 0 | Not yet recruiting --> Withdrawn
- | Enrollment change, Trial withdrawal, Metastases: QUILT-3.088: NANT Pancreatic Cancer Vaccine (clinicaltrials.gov) - Aug 28, 2019
P2, N=0, Withdrawn, Sponsor: NantKwest, Inc.
N=558 --> 0 | Not yet recruiting --> Withdrawn N=1064 --> 0 | Not yet recruiting --> Withdrawn
- | Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date, Metastases: QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine (clinicaltrials.gov) - Aug 28, 2019
P1/2, N=0, Withdrawn, Sponsor: NantKwest, Inc.
N=1064 --> 0 | Not yet recruiting --> Withdrawn N=382 --> 0 | Trial completion date: Dec 2022 --> Aug 2019 | Active, not recruiting --> Withdrawn | Trial primary completion date: Jul 2020 --> Aug 2019
- | Trial primary completion date: QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed (clinicaltrials.gov) - Jul 15, 2019
P1/2, N=65, Active, not recruiting, Sponsor: NantKwest, Inc.
N=382 --> 0 | Trial completion date: Dec 2022 --> Aug 2019 | Active, not recruiting --> Withdrawn | Trial primary completion date: Jul 2020 --> Aug 2019 Trial primary completion date: May 2019 --> Dec 2019
- | Trial completion date, Trial primary completion date: QUILT-3.080: NANT Pancreatic Cancer Vaccine (clinicaltrials.gov) - Jul 15, 2019
P1b/2, N=173, Active, not recruiting, Sponsor: NantKwest, Inc.
Trial primary completion date: May 2019 --> Dec 2019 Trial completion date: May 2020 --> Dec 2019 | Trial primary completion date: May 2019 --> Dec 2019
- ||| Enrollment closed, Metastases: QUILT-3.071: QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine (clinicaltrials.gov) - May 17, 2019
P1b/2, N=332, Active, not recruiting, Sponsor: NantKwest, Inc.
Trial completion date: May 2020 --> Dec 2019 | Trial primary completion date: May 2019 --> Dec 2019 Recruiting --> Active, not recruiting
- || Enrollment closed: QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. (clinicaltrials.gov) - May 17, 2019
P1/2, N=79, Active, not recruiting, Sponsor: NantKwest, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Enrollment change, Trial withdrawal: QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine (clinicaltrials.gov) - May 14, 2019
P2, N=0, Withdrawn, Sponsor: NantKwest, Inc.
Recruiting --> Active, not recruiting N=376 --> 0 | Not yet recruiting --> Withdrawn
- | Enrollment change, Trial withdrawal: QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma. (clinicaltrials.gov) - May 13, 2019
P1b/2, N=0, Withdrawn, Sponsor: NantKwest, Inc.
N=376 --> 0 | Not yet recruiting --> Withdrawn N=427 --> 0 | Not yet recruiting --> Withdrawn
- || Enrollment closed, Trial primary completion date: QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed (clinicaltrials.gov) - May 13, 2019
P1/2, N=65, Active, not recruiting, Sponsor: NantKwest, Inc.
N=427 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2018 --> May 2019
- || Enrollment closed: QUILT-3.080: NANT Pancreatic Cancer Vaccine (clinicaltrials.gov) - May 13, 2019
P1b/2, N=173, Active, not recruiting, Sponsor: NantKwest, Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2018 --> May 2019 Recruiting --> Active, not recruiting
- ||| Enrollment closed, Metastases: QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine (clinicaltrials.gov) - May 13, 2019
P1/2, N=382, Active, not recruiting, Sponsor: NantKwest, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || Trial primary completion date: QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. (clinicaltrials.gov) - Apr 12, 2019
P1/2, N=79, Recruiting, Sponsor: NantKwest, Inc.
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2019 --> Dec 2019
- | Trial completion date, Trial primary completion date, Metastases: QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine (clinicaltrials.gov) - Oct 5, 2018
P1/2, N=382, Recruiting, Sponsor: NantKwest, Inc.
Trial primary completion date: Jan 2019 --> Dec 2019 Trial completion date: Dec 2020 --> Dec 2022 | Trial primary completion date: Dec 2019 --> Jul 2020
- | GI-6301 / BMS
Enrollment closed, Combination therapy, Metastases: QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma (clinicaltrials.gov) - Sep 18, 2018
P2, N=55, Active, not recruiting, Sponsor: NantCell, Inc.
Trial completion date: Dec 2020 --> Dec 2022 | Trial primary completion date: Dec 2019 --> Jul 2020 Recruiting --> Active, not recruiting
- | Enrollment open: QUILT-3.080: NANT Pancreatic Cancer Vaccine (clinicaltrials.gov) - Aug 10, 2018
P1b/2, N=173, Recruiting, Sponsor: NantKwest, Inc.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Enrollment open, Metastases: QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine (clinicaltrials.gov) - Aug 10, 2018
P1/2, N=382, Recruiting, Sponsor: NantKwest, Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| New P2 trial: QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer (clinicaltrials.gov) - Jul 2, 2018
P2, N=558, Not yet recruiting, Sponsor: NantKwest, Inc.
- ||||| New P2 trial, Metastases: QUILT-3.088: NANT Pancreatic Cancer Vaccine (clinicaltrials.gov) - Jun 19, 2018
P2, N=1064, Not yet recruiting, Sponsor: NantKwest, Inc.
- ||||| New P1/2 trial, Metastases: QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine (clinicaltrials.gov) - Jun 19, 2018
P1/2, N=382, Not yet recruiting, Sponsor: NantKwest, Inc.
- ||||| New P2 trial: QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine (clinicaltrials.gov) - Jun 11, 2018
P2, N=376, Not yet recruiting, Sponsor: NantKwest, Inc.
- | GI-6301 / BMS
Trial completion, Trial primary completion date: Cancer Vaccine Targeting Brachyury Protein in Tumors (clinicaltrials.gov) - Jan 29, 2018
P1, N=34, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Jan 2017 --> Mar 2016
- ||||| New P1/2 trial: QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. (clinicaltrials.gov) - Dec 29, 2017
P1/2, N=79, Recruiting, Sponsor: NantKwest, Inc.
- ||||| New P1/2 trial: QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed (clinicaltrials.gov) - Dec 29, 2017
P1/2, N=65, Recruiting, Sponsor: NantKwest, Inc.
- ||| Trial initiation date: QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy (clinicaltrials.gov) - Oct 30, 2017
P1/2, N=113, Not yet recruiting, Sponsor: NantKwest, Inc.
Active, not recruiting --> Completed | Trial primary completion date: Jan 2017 --> Mar 2016 Initiation date: Aug 2017 --> Dec 2017
- ||| Trial initiation date: QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy (clinicaltrials.gov) - Oct 30, 2017
P1/2, N=67, Not yet recruiting, Sponsor: NantKwest, Inc.
Initiation date: Aug 2017 --> Dec 2017 Initiation date: Sep 2017 --> Dec 2017
- ||| Trial initiation date: QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy (clinicaltrials.gov) - Oct 30, 2017
P1/2, N=79, Not yet recruiting, Sponsor: NantKwest, Inc.
Initiation date: Sep 2017 --> Dec 2017 Initiation date: Aug 2017 --> Dec 2017
- ||| Trial initiation date: QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors (clinicaltrials.gov) - Oct 30, 2017
P1/2, N=85, Not yet recruiting, Sponsor: NantKwest, Inc.
Initiation date: Aug 2017 --> Dec 2017 Initiation date: Aug 2017 --> Dec 2017
- ||| Trial initiation date: QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy (clinicaltrials.gov) - Oct 30, 2017
P1/2, N=113, Not yet recruiting, Sponsor: NantKwest, Inc.
Initiation date: Aug 2017 --> Dec 2017 Initiation date: Aug 2017 --> Dec 2017
- ||| Trial initiation date, Metastases: QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC (clinicaltrials.gov) - Oct 30, 2017
P1/2, N=79, Not yet recruiting, Sponsor: NantKwest, Inc.
Initiation date: Aug 2017 --> Dec 2017 Initiation date: Aug 2017 --> Dec 2017
- ||| Trial initiation date: QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy (clinicaltrials.gov) - Oct 30, 2017
P1/2, N=67, Not yet recruiting, Sponsor: NantKwest, Inc.
Initiation date: Aug 2017 --> Dec 2017 Initiation date: Aug 2017 --> Dec 2017
- ||| Trial initiation date: QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy (clinicaltrials.gov) - Oct 30, 2017
P1/2, N=67, Not yet recruiting, Sponsor: NantKwest, Inc.
Initiation date: Aug 2017 --> Dec 2017 Initiation date: Aug 2017 --> Dec 2017
- ||||| New P1/2 trial: QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy (clinicaltrials.gov) - Jun 22, 2017
P1/2, N=113, Not yet recruiting, Sponsor: NantCell, Inc.